Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 788 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Macular Degenerative Disease Clear all
Withdrawn Phase 2 Interventional

Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD

NCT02563782
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Sub-retinal transplantation of MA09-hRPE cells, tacrolimus and mycophenolate mofetil, Placebo tacrolimus and mycophenolate mofetil, Sham Surgery
Biological · Drug · Procedure
Lead sponsor
Astellas Institute for Regenerative Medicine
Industry
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Jun 10, 2026, 8:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)

NCT01682382
View directory record Official record
Conditions
Age-related Macular Degeneration, Choroidal Neovascular Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
60 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2014 · Synced Jun 10, 2026, 8:59 PM EDT
Recruiting Not applicable Interventional

Factors in Learning And Plasticity: Macular Degeneration

NCT05454124
View directory record Official record
Conditions
Central Visual Impairment, Macular Degeneration
Interventions
Training visual sensitivity, Combination training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jun 10, 2026, 8:59 PM EDT
Completed No phase listed Observational

Genetic Load and Phenotype in Aggressive AMD

NCT01650948
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
RetnaGene AMD LDT
Device
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 19, 2014 · Synced Jun 10, 2026, 8:59 PM EDT
Completed Phase 2 Interventional

GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

NCT03815825
View directory record Official record
Conditions
Macular Degeneration, Geographic Atrophy
Interventions
IONIS-FB-LRx, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
55
States / cities
Phoenix, Arizona • Sun City, Arizona • Beverly Hills, California + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jun 10, 2026, 8:59 PM EDT
Completed Not applicable Interventional

Design and Clinical Evaluation of a Smartphone-based Low Vision Enhancement System

NCT03728660
View directory record Official record
Conditions
Low Vision
Interventions
Virtual bioptic magnification with large field of view, Full field magnification with small field of view
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
14 Years to 100 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Jun 10, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.

NCT00463320
View directory record Official record
Conditions
Macular Degeneration, Age-related Macular Degeneration
Interventions
Pazopanib eye drops and Allergen Refresh Plus eye drops
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Fargo, North Dakota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2012 · Synced Jun 10, 2026, 8:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate

NCT01314417
View directory record Official record
Conditions
Non-infectious Intermediate and Posterior Uveitis
Interventions
Methotrexate
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Jun 10, 2026, 8:59 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT02087085
View directory record Official record
Conditions
Geographic Atrophy, Macular Degeneration
Interventions
400 µg Brimonidine Implant, Sham
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
55 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
23
States / cities
Phoenix, Arizona • La Jolla, California • Mountain View, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Jun 10, 2026, 8:59 PM EDT
Completed No phase listed Observational

AMD Phenotype and Genotype Study

NCT01778491
View directory record Official record
Conditions
Age-Related Macular Degeneration, AMD
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
60 Years to 90 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jun 10, 2026, 8:59 PM EDT
Terminated Phase 2 Interventional Results available

A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT04607148
View directory record Official record
Conditions
Macular Degeneration, Age-Related, Geographic Atrophy
Interventions
Galegenimab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
60 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Bakersfield, California • Encino, California • Fullerton, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Jun 10, 2026, 8:59 PM EDT
Completed Phase 4 Interventional Results available

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

NCT02689518
View directory record Official record
Conditions
Macular Degeneration, Wet Macular Degeneration
Interventions
Intravitreal aflibercept injection
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Jun 10, 2026, 8:59 PM EDT
Terminated No phase listed Observational

GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

NCT03894020
View directory record Official record
Conditions
Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Retinal Degeneration, Geographic Atrophy, Macular Atrophy
Interventions
Not listed
Lead sponsor
Gyroscope Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Jun 10, 2026, 8:59 PM EDT
Completed No phase listed Observational

Blood and Saliva Sample Collection for AREDS 2

NCT01553474
View directory record Official record
Conditions
Age-Related Macular Degeneration, Eye Diseases
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 85 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Jun 10, 2026, 8:59 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT

NCT06805474
View directory record Official record
Conditions
Macular Degeneration, Geographic Atrophy, Stargardt Disease
Interventions
Observational
Other
Lead sponsor
Nanoscope Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Jun 10, 2026, 8:59 PM EDT
Completed No phase listed Observational

Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

NCT05037396
View directory record Official record
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Brolucizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
9,457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Jun 10, 2026, 8:59 PM EDT
Recruiting Not applicable Interventional

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

NCT06662162
View directory record Official record
Conditions
Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
i-Lumen AMD
Device
Lead sponsor
i-Lumen Scientific AUS PTY LTD
Industry
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Manchester, Connecticut • Lemont, Illinois • Fort Worth, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 10, 2026, 8:59 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride

NCT01802866
View directory record Official record
Conditions
Geographic Atrophy
Interventions
ACU-4429, Placebo
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
55 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 8:59 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)

NCT01115556
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Other
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Jun 10, 2026, 8:59 PM EDT
Recruiting Phase 2 Interventional

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

NCT06962839
View directory record Official record
Conditions
Macular Edema
Interventions
BI 1815368, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
23
States / cities
Arcadia, California • Huntington Beach, California • Modesto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jun 10, 2026, 8:59 PM EDT
Not listed No phase listed Observational

Assessment of Visual Function With a Portable Brain-computer Interface

NCT03760055
View directory record Official record
Conditions
Glaucoma, Age Related Macular Degeneration, Optic Neuropathy, Retinal Degeneration
Interventions
nGoggle
Device
Lead sponsor
NGoggle
Industry
Eligibility
18 Years to 90 Years
Enrollment
200 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Jun 10, 2026, 8:59 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab

NCT01402544
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
ranibizumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Bakersfield, California • La Jolla, California • Santa Barbara, California + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jun 10, 2026, 8:59 PM EDT
Completed Phase 4 Interventional

Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period

NCT07090044
View directory record Official record
Conditions
Vein Occlusion, Macular Degeneration Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy
Interventions
Bromfenac Sodium 0.07%, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly, Propylene Glycol Preservative-free Artificial Tears
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Jun 10, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD

NCT01013376
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
MC-1101, Vehicle
Drug
Lead sponsor
MacuCLEAR, Inc.
Industry
Eligibility
50 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 12, 2009 · Synced Jun 10, 2026, 8:59 PM EDT